Tenax shares nosedive as heart failure drug fails in Phase 3
Phase 3negativeTNX-103Negative
AI Analysis
Summary
Tenax Therapeutics' TNX-103 failed to meet its primary endpoint in a Phase 3 heart failure trial, with patients not showing significantly better functional performance. The company reported encouraging biomarker improvements and positive signals in subgroup analyses of elderly and severely ill patients.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Not Met
Outcome Details
Did not show significantly better functional performance in primary endpoint; however, biomarker improvements and subgroup analyses in elderly and more severe patients showed positive signals
Importance:8/10
Sentiment:
-0.80
Phase 3 failureheart failureclinical trialprimary endpoint missedbiomarker improvement
Read the original article
Published by BioSpace on August 10, 2026 12:57 PM